PMID- 29512715
OWN - NLM
STAT- MEDLINE
DCOM- 20180910
LR  - 20181114
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 41
IP  - 6
DP  - 2018 Jun
TI  - miR‑377 targets CUL4A and regulates metastatic capability in ovarian cancer.
PG  - 3147-3156
LID - 10.3892/ijmm.2018.3540 [doi]
AB  - The incidence and recurrence rates of ovarian cancer are still high, and once the 
      disease metastasizes, it is nearly always fatal. Cullin 4A (CUL4A) serves a 
      significant role in tumourigenesis and tumour progression; however, the effect 
      and mechanisms underlying CUL4A overexpression are still unknown. The role of 
      microRNAs (miRs) in the regulation of metastatic capability in ovarian cancer 
      cell lines was investigated. The interaction between miR‑377 and CUL4A was 
      investigated using bioinformatics analyses and dual‑luciferase reporter assays. 
      Furthermore, miR‑377 mRNA and protein levels were detected using reverse 
      transcription‑quantitative polymerase chain reaction and western blotting, 
      respectively and cell migration and invasion were detected using a Transwell 
      assay. Results revealed that CUL4A expression was negatively associated with 
      miR‑377 levels in ovarian cancer tissues and cell lines. Through in silico 
      analysis, the targeting effect of miR‑377 on CUL4A was verified. Ectopic 
      expression of miR‑377 in SKOV3 cells downregulated the level of CUL4A, and 
      significantly reduced the migratory ability of the cells. miR‑377 overexpression 
      led to reduced activity of the Wnt/beta‑catenin signaling pathway, and regulated the 
      expression of matrix metalloproteinase‑2, and 9, and epithelial‑mesenchymal 
      transition (EMT)‑associated protein. These results suggested that miR‑377 is a 
      significant negative regulator of CUL4A that controls cancer cell progression in 
      ovarian cancer cell lines.
FAU - Yu, Rufen
AU  - Yu R
AD  - Department of Obstetrics and Gynecology, Ruian People's Hospital, The Third 
      Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325200, P. 
      R. China.
FAU - Cai, Limei
AU  - Cai L
AD  - Department of Obstetrics and Gynecology, Ruian People's Hospital, The Third 
      Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325200, P. 
      R. China.
FAU - Chi, Yingui
AU  - Chi Y
AD  - Department of Obstetrics and Gynecology, Ruian People's Hospital, The Third 
      Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325200, P. 
      R. China.
FAU - Ding, Xiangcui
AU  - Ding X
AD  - Department of Obstetrics and Gynecology, Ruian People's Hospital, The Third 
      Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325200, P. 
      R. China.
FAU - Wu, Xueqing
AU  - Wu X
AD  - Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou 
      Medical University, The First Provincial Wenzhou Hospital of Zhejiang, Wenzhou, 
      Zhejiang 325000, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20180307
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (CUL4A protein, human)
RN  - 0 (Cullin Proteins)
RN  - 0 (MIRN377 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Transformation, Neoplastic/genetics/pathology
MH  - Cullin Proteins/genetics/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics/physiology
MH  - Humans
MH  - MicroRNAs/genetics/*metabolism
MH  - Neoplasm Metastasis/genetics/*physiopathology
MH  - Ovarian Neoplasms/genetics/*metabolism/pathology
PMC - PMC5881808
EDAT- 2018/03/08 06:00
MHDA- 2018/09/11 06:00
PMCR- 2018/03/07
CRDT- 2018/03/08 06:00
PHST- 2017/05/17 00:00 [received]
PHST- 2018/01/31 00:00 [accepted]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2018/09/11 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
PHST- 2018/03/07 00:00 [pmc-release]
AID - ijmm-41-06-3147 [pii]
AID - 10.3892/ijmm.2018.3540 [doi]
PST - ppublish
SO  - Int J Mol Med. 2018 Jun;41(6):3147-3156. doi: 10.3892/ijmm.2018.3540. Epub 2018 
      Mar 7.